| Richard Charles Arbogast, MD | |
|
269 W 3300s, Ogden, UT 84401 | |
| (801) 393-5355 | |
| (801) 394-4609 |
| Full Name | Richard Charles Arbogast |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 269 W 3300s, Ogden, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376613141 | NPI | - | NPPES |
| O6072 | Medicaid | UT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 1634071205 (Utah) | Secondary |
| 207Q00000X | Family Medicine | 1634071205 (Utah) | Primary |
| Entity Name | Odyssey House Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033143706 PECOS PAC ID: 2365458833 Enrollment ID: O20060222000116 |
News Archive
In an advance that could help ease health and environmental concerns about the emerging nanotechnology industry, scientists are reporting development of technology for changing the behavior of nanoparticles in municipal sewage treatment plants - their main gateway into the environment. Their study will be published online November 12 in ACS' journal Environmental Science & Technology.
In a discovery with implications for future drug design, scientists from the Florida campus of The Scripps Research Institute have shown an unprecedented mechanism for how a natural antibiotic with antitumor properties incorporates sulfur into its molecular structure, an essential ingredient of its antitumor activity.
A study from the University of Calgary's Hotchkiss Brain Institute shows there is evidence to support a new drug therapy called nabilone to treat diabetic neuropathy, or nerve pain.
How much chocolate would you need to eat to be satisfied? Less than half as much as you think, according to this recently published Cornell University snacking study. Using chocolate chips, apple pie, and potato chips, researchers Ellen van Kleef, Mitsuru Shimizu, and Brian Wansink designed a study to determine if people who were given smaller portions of snack foods would feel hungrier or satisfied fifteen minutes after eating.
Celtaxsys, Inc., a private biopharmaceutical company developing a new class of drugs to treat chronic inflammatory disorders, today announced the initiation of a first-in-human Phase 1 clinical study of CTX-4430, which blocks the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Richard Charles Arbogast, MD 2240 Adams Ave, Ogden, UT 84401-1511 Ph: (801) 393-5355 | Richard Charles Arbogast, MD 269 W 3300s, Ogden, UT 84401 Ph: (801) 393-5355 |
News Archive
In an advance that could help ease health and environmental concerns about the emerging nanotechnology industry, scientists are reporting development of technology for changing the behavior of nanoparticles in municipal sewage treatment plants - their main gateway into the environment. Their study will be published online November 12 in ACS' journal Environmental Science & Technology.
In a discovery with implications for future drug design, scientists from the Florida campus of The Scripps Research Institute have shown an unprecedented mechanism for how a natural antibiotic with antitumor properties incorporates sulfur into its molecular structure, an essential ingredient of its antitumor activity.
A study from the University of Calgary's Hotchkiss Brain Institute shows there is evidence to support a new drug therapy called nabilone to treat diabetic neuropathy, or nerve pain.
How much chocolate would you need to eat to be satisfied? Less than half as much as you think, according to this recently published Cornell University snacking study. Using chocolate chips, apple pie, and potato chips, researchers Ellen van Kleef, Mitsuru Shimizu, and Brian Wansink designed a study to determine if people who were given smaller portions of snack foods would feel hungrier or satisfied fifteen minutes after eating.
Celtaxsys, Inc., a private biopharmaceutical company developing a new class of drugs to treat chronic inflammatory disorders, today announced the initiation of a first-in-human Phase 1 clinical study of CTX-4430, which blocks the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H).
› Verified 4 days ago
Scott Allen Andelin, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4403 Harrison Blvd, Ste A-700, Ogden, UT 84403 Phone: 801-387-5300 | |
John M Hemmersmeier, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5740 Crestwood Dr, Ogden, UT 84405 Phone: 801-479-7771 Fax: 801-479-7795 | |
Kristine M Oates, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 4403 Harrison Blvd, Ste. A700, Ogden, UT 84403 Phone: 801-387-5300 Fax: 801-387-5335 | |
Benjamin Zachary Larsen, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4403 Harrison Blvd Ste 700a, Ogden, UT 84403 Phone: 801-387-5300 Fax: 801-387-5333 | |
Robert L Adams, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1355 Hinkley Dr, Ogden, UT 84401 Phone: 801-387-6050 | |
Mary Ellen Mason, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4650 Harrison Blvd, Ogden, UT 84403 Phone: 801-475-3010 Fax: 801-475-3001 | |
Brett Wayne Martindale, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4700 Harrison Blvd, Ogden, UT 84403 Phone: 801-475-3300 Fax: 801-475-3301 |